Cats A
Agents Actions. 1976 Feb;6(1-3):355-63. doi: 10.1007/BF01972255.
In a combined clinical trial with gold in patients with rheumatoid arthritis (RA) 95 patients were treated with a high initial dosage of 2,500 mg aurothioglucose in 21 weeks. Afterwards 48 of these patients received a maintenance dosage of gold and 47 patients placebo injections. Another group of 101 patients received 1,000 mg gold in 21 weeks. Finally a maintenance dose of gold was administered to 49 of these patients, to the other 52 patients placebo injections were administered. For the treatment of RA a high dosage of a gold compound offers no advantage over a low dosage. After a high dosage one can expect a significantly higher number of side effects. The development of toxicity does not influence the ultimate results. A second course of gold has hardly any benificial effect. Prolonged administration of gold is usually well-tolerated; whether it has substantial and sustained therapeutic value remains dubious. Progression of radiological abnormalities can be observed at the same moment that signs and other symptoms of the disease show improvement.
在一项针对类风湿性关节炎（RA）患者的金制剂联合临床试验中，95名患者在21周内接受了2500毫克硫代葡萄糖金的高初始剂量治疗。之后，其中48名患者接受金制剂维持剂量治疗，47名患者接受安慰剂注射。另一组101名患者在21周内接受1000毫克金制剂治疗。最后，其中49名患者接受金制剂维持剂量治疗，另外52名患者接受安慰剂注射。对于类风湿性关节炎的治疗，高剂量金化合物并不比低剂量更具优势。高剂量治疗后，副作用的数量预计会显著增加。毒性的发展并不影响最终结果。再次使用金制剂几乎没有任何有益效果。长期使用金制剂通常耐受性良好；其是否具有实质性和持续的治疗价值仍不确定。在疾病的体征和其他症状出现改善的同时，可以观察到放射学异常的进展。
